01—Abstract
Summary
Summary of the 8-K filed July 14, 2025. Cited figures are marked; the original filing is the authoritative source.
Becton, Dickinson and Company (BDX) has entered into definitive agreements to combine its Biosciences and Diagnostic Solutions business with Waters Corporation through a Reverse Morris Trust transaction.
This strategic move involves separating the target business into a new entity, SpinCo, which will then merge with a subsidiary of Waters. As a result of this transaction, BDX will receive approximately $4 billiona in cash, and its shareholders will own a 39.2% stake in the combined Waters entity. This transaction is expected to reshape BDX's business portfolio and provide significant capital for future endeavors.
The deal has received unanimous approval from the Boards of Directors of both BDX and Waters. The transaction is structured through a separation of BDX's relevant business, a cash distribution to BDX, a spin-off of the new entity to BDX shareholders, and a subsequent merger with a Waters subsidiary. The consummation of this transaction is subject to various closing conditions, including regulatory approvals and the satisfaction of financing conditions.
02—Key points
Key Highlights
- BDX is combining its Biosciences and Diagnostic Solutions business with Waters Corporation via a Reverse Morris Trust transaction.
- BDX will receive approximately $4 billion in cash from the transaction.
- BDX shareholders will own 39.2% of the combined Waters entity post-transaction.
- The transaction involves a separation of the business, a cash distribution, a spin-off, and a merger.
- Both BDX and Waters' Boards of Directors have unanimously approved the definitive agreements.
- The transaction is subject to customary closing conditions, including regulatory approvals and financing.
- Key definitive agreements include a Separation Agreement and an Agreement and Plan of Merger.
03—Questions
Frequently Asked Questions
What is the main purpose of this transaction for Becton Dickinson?
The primary purpose of this transaction for Becton Dickinson is to combine its Biosciences and Diagnostic Solutions business with Waters Corporation. This strategic move will result in BDX receiving a significant cash infusion of approximately $4 billion and its shareholders gaining a substantial equity stake in the combined entity, allowing BDX to potentially refocus its resources and capital.
How will BDX shareholders be affected by this deal?
Following the completion of the transaction, BDX shareholders will own 39.2% of the outstanding common stock of Waters Corporation. This means they will become shareholders in a larger, combined company that includes BDX's Biosciences and Diagnostic Solutions business and Waters' existing operations.
What are the key steps involved in this Reverse Morris Trust transaction?
The transaction involves several key steps: 1) BDX separates its Biosciences and Diagnostic Solutions business into a new subsidiary, SpinCo. 2) SpinCo distributes $4 billion in cash to BDX. 3) BDX spins off SpinCo shares to its shareholders. 4) SpinCo immediately merges with a subsidiary of Waters, with SpinCo becoming a wholly-owned subsidiary of Waters.
What are the main conditions that need to be met for this transaction to close?
The transaction is subject to several conditions, including the completion of the separation of the business, receipt of customary solvency and surplus opinions, completion of certain financing transactions, satisfaction of conditions under the Merger Agreement (including Waters shareholder approval), receipt of antitrust approvals (like HSR), effectiveness of registration statements, receipt of a private letter ruling from the IRS, and tax opinions from both companies.
04—Continue